| 引用本文: |
雷彩云,毛丹,丁陈陈,施利,张绍钒,林丰夏,黄建华,刘新义,马进安,雷三林,张英进,张四方.健脾解毒方联合化疗治疗大肠癌术后患者的临床观察[J].湖南中医药大学学报,2016,36(11):64-67[点击复制] |
|
| |
|
|
| 本文已被：浏览 2871次 下载 1540次 |
| 健脾解毒方联合化疗治疗大肠癌术后患者的临床观察 |
| 雷彩云,毛丹,丁陈陈,施利,张绍钒,林丰夏,黄建华,刘新义,马进安,雷三林,张英进,张四方 |
| (中南大学湘雅二医院, 湖南 长沙 410011;湖南中医药大学药学院, 湖南 长沙 410208) |
| 摘要: |
| 目的 观察健脾解毒方联合化疗治疗II-III期大肠癌术后患者的临床疗效及其对免疫功能的影响。方法 将40例大肠癌患者按随机数字表法分为治疗组、对照组各20例。两组患者化疗均采用FOLFOX4化疗方案，治疗组加服健脾解毒方汤剂（每日1剂，连服8周），化疗每2周重复1次，1次为1个周期，连用4个周期后观察两组临床疗效及其免疫功能的变化。结果 治疗结束后治疗组中医证候改善的总有效率高于对照组，差异有统计学意义（P<0.05）；两组患者的中医证候总积分均较治疗前有所改善，两组间比较差异有统计学意义（P<0.01）；治疗后治疗组在KPS评分疗效及体质量增加方面优于对照组，差异有统计学意义（P<0.05）；在免疫学指标CD3+、CD4+、CD4+/CD8+值改善方面优于对照组，差异具有显著统计学意义（P<0.01）。结论 健脾解毒方能提高大肠癌化疗患者的临床疗效，改善生活质量，并增强机体免疫力。 |
| 关键词: 大肠癌 健脾解毒方 化疗 临床疗效 免疫功能 |
| DOI：10.3969/j.issn.1674-070X.2016.11.017 |
| 投稿时间：2016-08-25 |
| 基金项目:国家自然科学基金面上项目（81273722）。 |
|
| Clinical Observation of Jianpi Jiedu Fang Combined with Chemotherapy on the Treatment of Postoperative Patients with Colorectal Cancer |
| LEI Caiyun,MAO Dan,DING Chenchen,SHI Li,ZHANG Shaofan,LIN Fengxia,HUNAG Jianhua,LIU Xinyi,MA Jinan,LEI Sanlin,ZHANG Yingjin,ZHANG Sifang |
| (The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China;School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China) |
| Abstract: |
| Objective To observe the clinical efficacy of Jianpi Jiedu Fang (JPJDF) combined with chemotherapy on the treatment of patients with stage II-III colorectal cancer after operation and its effects on immune function. Methods The 40 cases of colorectal cancer were divided into two groups, treatment group and control group, 20 cases in each group. Patients of two groups were treated with FOLFOX4 chemotherapy, but the treatment group was given JPJDF(one dose every day, continuously for 8 weeks). Every 2 weeks repeated 1 times, 1 times for 1 cycles, the clinical efficacy and immune function in the two groups were observed after 4 cycles. Results After the end of observation, the total efficiency of the treatment group was higher than that of the control group (P<0.05); the total scores of TCM syndromes in patients of the two groups were improved after treatment, there were differences between the two groups (P<0.01). After the end of treatment, the KPS score of treatment group was better than the control group, the difference was statistically significant (P<0.05); the CD3+, CD4+, CD4+/CD8+ index value was better than the control group, the difference was significant (P<0.01). Conclusion JPJDF can increasethe clinical efficacy, improve the quality of life and enhance the immune function of patients with colorectal cancer. |
| Key words: colorectal cancer Jianpi Jiedu Fang chemotherapy clinical efficacy immune function |
|
二维码（扫一下试试看！） |
|
|
|
|
